FeesSafety
Pluang+

Columbus McKinnon reports 107% sales growth, raises FY27 guidance after Kito Crosby acquisition boosts performance.

Company Fundamentals
03 Nov 2026, 13:30 WIB
PRNewsWire
View Source
Bullish
Columbus McKinnon reports 107% sales growth, raises FY27 guidance after Kito Crosby acquisition boosts performance.

Columbus McKinnon Corporation posted a 107% year-over-year increase in net sales for Q2 FY27, driven largely by its acquisition of Kito Crosby Limited. The company also saw a 122% rise in orders and a book-to-bill ratio of 1.0x, indicating strong demand and efficient order conversion. Despite a net loss due to acquisition-related expenses, adjusted net income rose 74%, and adjusted EBITDA margin improved by 520 basis points. The company raised its full-year FY27 guidance for net sales, adjusted EBITDA, and adjusted EPS, reflecting confidence in continued growth and successful integration of Kito Crosby.

Columbus McKinnon's Q2 FY27 performance and guidance update is presented here with Pluang's Industrials sector market data as of Nov 03, 2026 17:41 WIB: Among 135 priced US Industrials stocks, 72 advanced while 53 declined. Notable movers include TRMD at USD 41.03 with a 3.04% gain and 100% buy order activity, FPS at USD 25.21 up 2.65%, and CNI at USD 123.84 down 2.32% with 84% sell orders. The most notable figure is TRMD's full buy-side order activity.

More News

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...

Company Fundamentals
Bullish
2 hours ago
Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...

Market News
Bullish
2 hours ago
Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...

Market News
Bullish
2 hours ago
Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...

Company Fundamentals
Neutral
3 hours ago
Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones Inc. announced a conference call for November 4, 2026, at 10:00 AM EST to discuss its third quarter 2026 financial results. The call is open to investors, analysts, and interested parties and will be webcast live with a recording availab...

Company Fundamentals
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App